Deborah Elstein

Deborah Elstein

Auto-generated profile, based on publicly available information

Deborah Elstein

Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2014 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
MSMichael S. Schimmel
Michael S. Schimmel
RBRuben Bromiker
Ruben Bromiker
CHCathy Hammerman
Cathy Hammerman
LCLila Chertman
Lila Chertman
AIAlexander Ioscovich
Alexander Ioscovich
DEDeborah Elstein
Deborah Elstein

1 October 2007 in Blood
Verified
Journal Article
Closed access
PDF file
DEDeborah Elstein
Deborah Elstein
ADAltoon Dweck
Altoon Dweck
DADrorit Attias
Drorit Attias
IHIrith Hadas-Halpern
Irith Hadas-Halpern
SZShoshana Zevin
Shoshana Zevin
AZAri Zimran
Ari Zimran
Enzyme replacement therapy (ERT) with imiglucerase reduces hepatosplenomegaly and improves hematologic parameters in Gaucher disease type 1 within 6-24 months. Miglustat reduces organomegaly, improves hematologic parameters, and reverses bone marrow infiltration. This trial evaluates miglustat in patients clinically stable on ERT. Tolerability of miglustat and imiglucerase, alone and in combination, pharmacokinetic profile, organ reduction, and chitotriosidase activity were assessed. Thirty-six patients stable on imiglucerase were randomized into this phase II, open-label trial. Statistically significant changes from baseline were assessed (paired t test) on primary objectives with secondary analyses on biochemical and safety parameters. Liver and spleen volume were unchanged in switched patients. No significant differences were seen between groups regarding mean change in hemoglobin. Mean change in platelet counts was only significant between miglustat and imiglucerase groups (P = .035). Chitotriosidase activity remained stable. In trial extension, clinical endpoints were generally maintained. Miglustat was well tolerated alone or in combination. Miglustat's safety profile was consistent with previous trials; moreover, no new cases of peripheral neuropathy were observed. Gaucher disease type 1 (GD1) parameters were stable in most switched patients. Combination therapy did not show benefit. Findings suggest miglustat could be an effective maintenance therapy in stabilized patients with GD1.

29 May 2003 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Closed access
PDF file
AZAri Zimran
Ari Zimran
DEDeborah Elstein
Deborah Elstein
Gaucher disease is caused by an enzymatic defect with consequent accumulation of glucocerebroside. Type I, the non–neuronopathic form, is rather common and panethnic. Patients may present with hepatosplenomegaly, anaemia, thrombocytopenia and skeletal or lung involvement. Enzyme replacement therapy ameliorates disease symptoms and signs; however, it involves lifelong intravenous therapy, is costly and is incapable of crossing the blood–brain barrier. Substrate reduction with N –butyldeoxynojirimycin (OGT 918) is a harbinger of oral iminosugars for glycolipid storage disorders. Long–term data in the seminal trial (100 mg three times per day), demonstrate safety and efficacy in adult type I patients naive to enzyme therapy, and suggest its application in patients unwilling or unable to receive enzyme replacement and tolerating side effects, including diarrhoea, weight loss, tremor and peripheral neuropathy (mostly reversible with dose reduction or withdrawal). Dose dependency was demonstrated with 50 mg three times per day. In patients stabilized on enzyme therapy switched from or in combination with enzyme, no deterioration in disease parameters was seen but side effects were as above. Although efficacy is less dramatic than enzyme treatment, it may be that plateaux are achieved asymptotically so therapeutic outcomes with OGT 918 may ultimately be comparable. Yet, given the above side effects and the lack of long–term experience, patients with very mild manifestations would probably not be appropriate candidates.

1 September 2012 in Gene
Verified
Journal Article
Closed access
DEDeborah Elstein
Deborah Elstein
ESElla Schachamorov
Ella Schachamorov
RBRachel Beeri
Rachel Beeri
GAGheona Altarescu
Gheona Altarescu

1 January 2015 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Open access
Ari ZimranAri Zimran
Ari Zimran
DGDerlis Emilio Gonzalez-Rodriguez
Derlis Emilio Gonzalez-Rodriguez
AAAya Abrahamov
Aya Abrahamov
DEDeborah Elstein
Deborah Elstein
APAlona Paz
Alona Paz
RCRaul Chertkoff
Raul Chertkoff
Taliglucerase alfa is a plant cell-expressed beta-glucocerebrosidase approved in the United States, Israel, Australia, Canada, and other countries for enzyme replacement therapy in adults with Type 1 Gaucher disease (GD), for treatment of pediatric patients in the United States, Australia, and Canada, and for the hematologic manifestations of Type 3 GD in pediatric patients in Canada. This multicenter, randomized, double-blind, parallel-dose, 12-month study assessed efficacy and safety of taliglucerase alfa in pediatric patients with GD. Eleven children were randomized to taliglucerase alfa 30U/kg (n=6) or 60U/kg (n=5) per infusion every other week. From baseline to month 12, the following changes were noted in the taliglucerase alfa 30-U/kg and 60-U/kg dose groups, respectively: median hemoglobin concentrations increased by 12.2% and 14.2%; the interquartile ranges of median percent change in hemoglobin levels from baseline were 20.6 and 10.4, respectively; mean spleen volume decreased from 22.2 to 14.0 multiples of normal (MN) and from 29.4 to 12.9 MN; mean liver volume decreased from 1.8 to 1.5 MN and from 2.2 to 1.7 MN; platelet counts increased by 30.9% and 73.7%; and chitotriosidase activity was reduced by 58.5% and 66.1%. Nearly all adverse events were mild/moderate, unrelated to treatment, and transient. One patient presented with treatment-related gastroenteritis reported as a serious adverse event due to the need for hospitalization for rehydration. No patient discontinued. These data suggest that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD. This study was registered at www.clinicaltrials.gov as NCT01132690.

1 June 2011 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
DEDeborah Elstein
Deborah Elstein
AFA. Joseph Foldes
A. Joseph Foldes
DZDavid Zahrieh
David Zahrieh
GCGabriel M. Cohn
Gabriel M. Cohn
MDMaja Djordjevic
Maja Djordjevic
AZAri Zimran
Ari Zimran